Step into the future
Daily Editorial by Erica Martinelli, Associate Editor of the ESMO Congress Daily - Monday October 2nd 2012
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Daily Editorial by Erica Martinelli, Associate Editor of the ESMO Congress Daily - Monday October 2nd 2012
At a Presidential Symposium during ESMO 2012 in Vienna, Professor Florian Lordick from the University Clinic Leipzig and the University Cancer Centre (UCCL), Leipzig, Germany, presented data from the open-label randomised, controlled Phase 3 EXPAND trial of cetuximab in combination with capecitabine and cisplatin as first-line treatment for advanced gastric cancer (LBA3). The rationale for this trial came from previous Phase 2 trial data which suggested that cetuximab, an epidermal growth factor receptor (EGFR) antibody, in combination with first-line fluoropyrimidine with irinotecan or platinum compounds shows promising activity.
In the oncology community, it is common knowledge that sarcomas are rare tumours. Indeed, their overall incidence is approximately five per 100,000 people every year, making the feasibility of conducting statistically powered clinical trials a significant challenge. Adding to this is the fact that sarcomas are made up of several different histological types, so conducting a clinical trial in one specific histological type of sarcoma is virtually impossible!
PETACC8 study suggest a benefit in several patient subgroups
The addition of bevacizumab (BEV) to 5-FU-based chemotherapy has been a standard 1st-line treatment option for patients with metastatic colorectal cancer (mCRC) for many years, although the use of this agent beyond progression is an area of ongoing debate. However, emerging data suggest that this question may soon be answered
Despite continuing advances in medicine and drug development technology, it remains very difficult for new cancer drugs to gain regulatory approval.
ESMO 2012 has proved our biggest and best congress yet with an astonishing 16,394 delegates.
Irinotecan plus bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma
A role of immunomodulation after successful first-line treatment
Sorafenib became the standard treatment for advanced HCC five years ago after findings from the SHARP trial showed that treatment with this multi-targeted tyrosine kinase inhibitor (TKI) resulted in a 2.8 month improvement in overall survival (OS) compared with placebo. However, since then, results from Phase 3 trials evaluating targeted agents in this setting have been disappointing.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.